Class / Patent application number | Description | Number of patent applications / Date published |
514210700 | 7 or 8 amino acid residues in the peptide chain | 34 |
20100273724 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS - This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also disclosed | 10-28-2010 |
20110003756 | C5a Receptor Antagonists - The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure: | 01-06-2011 |
20110124584 | Compositions and methods for treating diseases - This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions. | 05-26-2011 |
20110136747 | USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWL DISEASE - The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. | 06-09-2011 |
20110144038 | HUMAN CD154-BINDING SYNTHETIC PEPTIDE AND USES THEREOF - The invention refers to a synthetic peptide comprising an amino acid sequence of seven residues in length, preferably flanked by 2 cysteine residues at both ends, which is capable of specifically recognizing human CD154 and blocking CD40:CD154 interaction, thereby inhibiting the biological effects depending on such interaction. The peptide of the invention, which is preferably in a cyclic form, is suitable for use for diagnostic and therapeutic applications, especially for the diagnosis and therapy of tumor, inflammatory diseases and transplant rejection. | 06-16-2011 |
20110152203 | TRANSFECTION AGENT - A transfection agent is provided that has lower toxicity and can be applied in the clinical setting. The transfection agent comprises a peptide surfactant. | 06-23-2011 |
20110183923 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 07-28-2011 |
20110245187 | MESENCHYMAL CELL PROLIFERATION PROMOTER AND SKELETAL SYSTEM BIOMATERIAL - It is found that a SVVYGLR peptide (SEQ ID NO: 1) can promote proliferation of mesenchymal cells such as marrow-derived mesenchymal stem cells and dental pulp cells. A carbonate apatite-collagen sponge containing the SVVYGLR peptide (SEQ ID NO: 1) is useful as a biomaterial for the regeneration of bone marrow or dental pulp. It becomes possible to provide a skeletal system biomaterial which is capable of promoting the proliferation of the mesenchymal cells and is useful as artificial bone marrow or artificial dental pulp for repairing a defect in a bone marrow tissue or a dental pulp tissue. | 10-06-2011 |
20110281805 | USE OF AN ANG-(1-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY - The present invention refers to a peptidic or non-peptidic angiotensin-(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and/or treatment of acute lung injury, preferably acute respiratory distress syndrome. | 11-17-2011 |
20120035117 | Process for Synthesis of Cyclic Octapeptide - This invention relates a process for preparing octreotide and derivatives thereof. The starting material, Cys(Trt)-2-Chlorotrityl resin is coupled with various amino acids to obtain a protected heptapeptide of formula (2): Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-2-Chlorotrityl resin. The linear protected peptide of formula (2) is cleaved from the support using TFA5TIS and water to yield linear protected peptide of formula (3) Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-OH Linear protected heptapeptide of formula (3) is deprotected to yield heptapeptide of formula (6): D-Phe-Cys-Phe-D-Tip-Lys-Thr-Cys-OH; which is cyclized using hydrogen peroxide and to the cyclic peptide of formula (7) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-OH; threoninol is coupled at C terminal to yield octreotide. Alternatively threoninol is coupled to the heptapeptide of formula (3) to yield protected octapeptide of formula (4) Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-Thr-OL which is subsequently deprotected to yield linear octapeptide of formula (5) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL and cyclized with hydrogen peroxide to yield cyclic octreotide with a yield of >95%. | 02-09-2012 |
20120058957 | COMPOSITIONS AND METHODS FOR COUNTERACTING EFFECTS OF REACTIVE OXYGEN SPECIES AND FREE RADICALS - Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by undesirable elevation of reactive oxygen species and other free radicals, to upregulate AP-1 gene expression, and to treat pain. The peptide compounds may be used as components of pharmaceuticals and dietary supplements. | 03-08-2012 |
20120172318 | PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F2alpha RECEPTOR - The invention relates to compositions which are useful for inhibiting prostaglandin F | 07-05-2012 |
20120225831 | Melanocortin-1 Receptor-Specific Linear Peptides - Melanocortin receptor-specific linear peptides of the formula | 09-06-2012 |
20120270812 | COMPOSITIONS, METHODS, AND KITS FOR DETERMINING AN ALKYL TRANSFERASE - The present invention relates to novel compounds as well as to compositions, methods, and kits comprising the compounds for determining an alkyltransferase (ATase), in particular an alkylguanine-DNA alkyl transferase (AGT). In general, the novel compounds provide for determining ATase levels, in particular for in vivo applications including, but not limited to, theranostic applications, in particular to cancer-related applications. | 10-25-2012 |
20120329729 | Methods for treating diabetic foot ulcers - The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers. | 12-27-2012 |
20120329730 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 12-27-2012 |
20130035296 | THERAPEUTIC PEPTIDES - The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted β amino acid, each of the substituting groups in the β amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition. | 02-07-2013 |
20130096074 | PROTEIN HYDROLYSATE ENRICHED IN PEPTIDES INHIBITING DPP-IV AND THEIR USE - Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder. | 04-18-2013 |
20130102547 | Use Of Tight Junction Antagonists To Treat Inflammatory Bowel Disease - The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. | 04-25-2013 |
20130281384 | LARAZOTIDE ACETATE COMPOSITIONS - The invention provides crystalline forms of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1), and salts of the peptide, which may further have associated water molecules. These salts and hydrated salts of the peptide and compositions comprising these materials have advantageous pharmaceutical properties. | 10-24-2013 |
20140296165 | USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWEL DISEASE - The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. | 10-02-2014 |
20140315831 | Synthesis of Libraries of Peptide Tertiary Amides - The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others. | 10-23-2014 |
20140323415 | ORGANIC COMPOUNDS - A pharmaceutical composition comprises octreotide acetate microparticles of linear poly(lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane. | 10-30-2014 |
20150031634 | ANGIOTENSIN PEPTIDES IN TREATING MARFAN SYNDROME AND RELATED DISORDERS - The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset. | 01-29-2015 |
20150057236 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME - Sirt5, a mitochondrial Sirtuin, has been identified herein as an efficient demalonylase and desuccinylase. Disclosed herein are assays to identify Sirt5 modulators based on this robust enzymatic activity. Sirt5-specific modulators can be used study the biological function of Sirt5 and to target Sirt5 activities in treating human diseases. | 02-26-2015 |
20150111837 | Method for Producing a Recombinant Peptide and Resultant Peptide - The invention relates to the field of biochemistry and concerns of recombinant method for production of peptides and the resulting peptides. In particular, the invention relates to peptides with the following general formula: | 04-23-2015 |
20150119341 | Melanocortin-1 Receptor-Specific Linear Peptides - Melanocortin receptor-specific linear peptides of the formula | 04-30-2015 |
20150307557 | Peptides - An internally-constrained cyclic oligopeptide comprising a ring of at least six amino acids for specifically binding to a target ligand, wherein the ring comprises a plurality of amino acid domains, each domain comprising at least two epitope-forming amino acids, and two or more associating functional groups positioned so that they form one or more intra-cyclic associations; whereby the cyclic oligopeptide is constrained in a single conformation so that the epitope-forming amino acids form an epitope in each domain, each epitope being capable of specifically binding to a target ligand. | 10-29-2015 |
20150320827 | NEW ITCH TREATMENT USING A COMBINATION OF NEUROKININ-1, GASTRIN RELEASING PEPTIDE, AND GLUTAMATE RECEPTOR ANTAGONISTS - Methods, and compositions are provided for inhibition of histamine and non-histamine dependent itch signal transmission or scratch behavior. In one aspect, the present invention further comprises administering to the subject an inhibitor of histamine-dependent itch signal transmission. In some cases, the inhibitor of histamine independent itch signal transmission comprises an NK-1 receptor antagonist or the inhibitor of histamine independent itch signal transmission comprises a GRP receptor antagonist. In some cases, the method comprises administering two inhibitors of histamine independent itch signal transmission. For example, the inhibitors of histamine independent itch signal transmission can comprise an NK-1 receptor antagonist and a GRP receptor antagonist. In another embodiment, the invention provides a method of treating itch comprising administering to a subject suffering from itch an NK-1 receptor antagonist, a GRP receptor antagonist. | 11-12-2015 |
20160015772 | HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME - Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions. | 01-21-2016 |
20160022760 | METHODS OF TREATING CELIAC DISEASE WITH LARAZOTIDE - The present invention provides compositions comprising Larazotide. The invention further provides methods of using the Larazotide compositions for treating celiac disease in symptomatic celiac disease patients. | 01-28-2016 |
20160151449 | USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWEL DISEASE | 06-02-2016 |
20160175389 | NEW PEPTIDES HAVING SPECIFICITY FOR THE LUNGS | 06-23-2016 |
20160375089 | MATERIALS AND METHODS FOR THE TREATMENT OF CELIAC DISEASE - The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease. | 12-29-2016 |